Identification of aurora kinase A as an unfavorable prognostic factor and potential treatment target for metastatic gastrointestinal stromal tumors
Although imatinib mesylate (IM) has revolutionized the management of gastrointestinal stromal tumors (GISTs), drug resistance remains a challenge. Previous studies have shown that the expression of aurora kinase A (AURKA) predicts recurrence in patients with primary, surgically resected GISTs. The c...
Main Authors: | , , , , , , , , , , , , , , |
---|---|
Format: | Online |
Language: | English |
Published: |
Impact Journals LLC
2014
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4147307/ |